이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Kiora Pharmaceuticals 관리

관리 기준 확인 4/4

Kiora Pharmaceuticals' CEO는 Brian Strem, Jul2021 에 임명되었습니다 의 임기는 3.08 년입니다. 총 연간 보상은 $ 802.27K, 51.9% 로 구성됩니다. 51.9% 급여 및 48.1% 보너스(회사 주식 및 옵션 포함). 는 $ 121.85K 가치에 해당하는 회사 주식의 1.02% 직접 소유합니다. 121.85K. 경영진과 이사회의 평균 재임 기간은 각각 2.8 년과 3.3 년입니다.

주요 정보

Brian Strem

최고 경영자

US$802.3k

총 보상

CEO 급여 비율	51.9%
CEO 임기	3.2yrs
CEO 소유권	1.0%
경영진 평균 재임 기간	2.9yrs
이사회 평균 재임 기간	3.4yrs

최근 관리 업데이트

Recent updates

Why Kiora Pharmaceuticals' (NASDAQ:KPRX) Earnings Are Better Than They Seem

May 21

Kiora pharmaceuticals regains compliance with Nasdaq minimum bid price requirement

Oct 13

CEO 보상 분석

Brian Strem 의 보수는 Kiora Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	US$3m
Mar 31 2024	n/a	n/a	US$2m
Dec 31 2023	US$802k	US$416k	-US$13m
Sep 30 2023	n/a	n/a	-US$13m
Jun 30 2023	n/a	n/a	-US$12m
Mar 31 2023	n/a	n/a	-US$12m
Dec 31 2022	US$714k	US$400k	-US$14m
Sep 30 2022	n/a	n/a	-US$17m
Jun 30 2022	n/a	n/a	-US$15m
Mar 31 2022	n/a	n/a	-US$15m
Dec 31 2021	US$659k	US$169k	-US$14m

보상 대 시장: Brian 의 총 보상 ($USD 802.27K )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 681.57K ).

보상과 수익: Brian 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Brian Strem (44 yo)

3.2yrs

테뉴어

US$802,274

보상

Dr. Brian M. Strem, Ph D., is Co-Founder and Director at Okogen, Inc. He served as Principal Financial and Accounting Officer of Kiora Pharmaceuticals, Inc. since June 16, 2022. He serves as President, Dir...

리더십 팀

이름	위치	테뉴어	보상	소유권
Brian Strem	President	3.2yrs	US$802.27k	1.02% $ 103.4k
Melissa Tosca	Chief Financial Officer	2yrs	US$387.48k	0.46% $ 46.6k
Eric Daniels	Chief Development Officer	2.9yrs	US$652.31k	0.63% $ 63.7k
Stefan Sperl	Executive Vice President of CMC & Operations	no data	데이터 없음	데이터 없음

2.9yrs

평균 재임 기간

44yo

평균 연령

경험이 풍부한 관리: KPRX 의 관리팀은 경험 ( 2.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Brian Strem	President	3.2yrs	US$802.27k	1.02% $ 103.4k
Lisa Walters-Hoffert	Independent Director	less than a year	데이터 없음	0.042% $ 4.3k
Daniel Durrie	Member of Scientific Advisory Board	7.5yrs	데이터 없음	데이터 없음
Praveen Tyle	Independent Chairman of the Board	16.3yrs	US$98.25k	0.17% $ 17.2k
Paul Karpecki	Member of Scientific Advisory Board	6.9yrs	데이터 없음	데이터 없음
Aron Shapiro	Director	3.4yrs	US$70.12k	0.10% $ 10.3k
Victor Perez	Member of Scientific Advisory Board	6.6yrs	데이터 없음	데이터 없음
David Hollander	Independent Director	2.8yrs	US$77.62k	0% $ 0
Erin Parsons	Non-Employee Independent Director	2.6yrs	US$84.50k	0.18% $ 18.0k
Allen Ho	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Christine Kay	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Francis Mah	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음

3.4yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 이사회: KPRX 의 이사회는 경험(평균 재직 기간 3.3 년)으로 간주됩니다.

Kiora Pharmaceuticals 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Kiora Pharmaceuticals, Inc. Announces Board and Committee Changes

Kiora Pharmaceuticals, Inc., Annual General Meeting, May 01, 2024

Kiora Pharmaceuticals, Inc. Announces Board Changes

Kiora Pharmaceuticals, Inc. Appoints Carmine Stengone as an Independent Director

High number of new directors

Kiora Pharmaceuticals, Inc. Appoints Melissa Tosca as Executive Vice President of Finance

Recent updates

Consensus EPS estimates increase by 64%, revenue downgraded

New major risk - Market cap size

Investor sentiment deteriorates as stock falls 16%

Kiora Pharmaceuticals, Inc. Announces Board and Committee Changes

Investor sentiment improves as stock rises 21%

Why Kiora Pharmaceuticals' (NASDAQ:KPRX) Earnings Are Better Than They Seem

Kiora Pharmaceuticals, Inc., Annual General Meeting, May 01, 2024

New major risk - Revenue and earnings growth

Price target decreased by 69% to US$3.83

New major risk - Share price stability

Price target increased by 42% to US$17.50

Kiora Pharmaceuticals, Inc. Announces Board Changes

New major risk - Revenue and earnings growth

Price target decreased by 56% to US$20.00

Kiora Pharmaceuticals, Inc. Appoints Carmine Stengone as an Independent Director

Kiora Pharmaceuticals Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Price target increased by 39% to US$65.50

Kiora Pharmaceuticals, Inc. and The Royal Adelaide Hospital Announce Dosing Has Commenced in the Phase 1 First-In-Human Trial for KIO-301

Kiora Pharmaceuticals, Inc. Receives Approval for Phase 2 Study of KIO-101 for Treatment of Ocular Presentation of Autoimmune Diseases

High number of new directors

Kiora pharmaceuticals regains compliance with Nasdaq minimum bid price requirement

Kiora Pharma announces 1-for-40 reverse stock split

Kiora Pharmaceuticals, Inc. Appoints Melissa Tosca as Executive Vice President of Finance

Kiora Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

High number of new directors

Kiora Pharmaceuticals, Inc., Annual General Meeting, Sep 23, 2022

Kiora Pharmaceuticals reports 1H results

Kiora gets US patent for KIO-201 use with antibiotics for eye wound healing

Kiora Pharmaceuticals prices $5.2M underwritten public offering

Kiora begins enrolling in phase 2 trial of wound healing eye drops KIO-201

Kiora Pharmaceuticals, Inc. Announces Brian M. Strem Will Assume Role of its Principal Financial and Accounting Officer

Kiora Pharmaceuticals Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)

Kiora Pharmaceuticals, Inc. announced delayed 10-Q filing

Kiora Pharmaceuticals, Inc. Appoints Susan L. Drexler as Interim Chief Financial Officer

Kiora Pharmaceuticals, Inc. announced delayed annual 10-K filing

Kiora Pharmaceuticals, Inc. Appoints Michael Meluzio as Principal Financial Officer and Principal Accounting Officer

Kiora Pharmaceuticals, Inc. Announces Resignation of Sarah Romano as Chief Financial Officer, Effective February 25, 2022

Kiora Pharmaceuticals, Inc. Announces Executive Changes

No longer forecast to breakeven

EyeGate Pharmaceuticals, Inc. Completes Target Enrollment in Phase 2 Proof-of-Concept Study to Evaluate PP-001 for the Treatment of Ocular Surface Inflammation

Price target decreased to US$11.83

EyeGate Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $10.750013 million.

Director Steven Boyd has left the company

Director I. Maher has left the company

EyeGate Pharmaceuticals, Inc. Announces First Patient Dosed for PP-001 in A Phase 2 Proof-Of-Concept Ocular Surface Inflammation Study

No longer forecast to breakeven

Price target decreased to US$13.08

Full year 2020 earnings released: US$1.77 loss per share (vs US$2.23 loss in FY 2019)

New 90-day high: US$7.30

EyeGate Pharmaceuticals, Inc. Announces Board Appointments

New 90-day high: US$6.63

EyeGate Pharmaceuticals announces $8M private placement

Price target raised to US$12.83

EyeGate Pharmaceuticals, Inc. (NasdaqCM:EYEG) entered into a share purchase agreement to acquire Panoptes Pharma GES.M.B.H for $15 million.

New 90-day high: US$5.21

EyeGate surge in premarket as it acquires Panoptes Pharma for $4M

Earnings beat expectations

New 90-day low: US$3.57

Price target lowered to US$11.17

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령